Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Affymetrix/Molecular Dynamics

This article was originally published in The Gray Sheet

Executive Summary

Affymetrix/Molecular Dynamics: Companies plan to establish a Genetic Analysis Technology Consortium (GATC) with the aim of providing "a unified technology platform to design, process, read and analyze DNA-arrays of DNA," the firms say. Through GATC, the companies will develop and publish a set of standards that will allow researchers to use uniform reader, data formats and reagents to process arrays made from multiple sources. Firms also sign a non-exclusive license agreement giving Molecular Dynamics rights to Affymetrix technology for commercializing low- and medium-density DNA arrays. The license does not apply to Affymetrix' light-directed synthesis technology, the companies say. Affymetrix will receive royalty payments on products sold by Molecular Dynamics. Affymetrix/ Amersham Pharmacia Biotech: Enter three-year, non-exclusive, worldwide sales and marketing agreement under which Amersham will sell Affymetrix' GeneChip probe arrays, reagents, systems and software...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009217

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel